BioSpace News Archive

A ketogenic diet, which primarily consists of foods like meat, fish, eggs, heavy cream, butter, oils and non-starchy vegetables like pea pods, carrots, broccoli and peppers, may be safe for people with multiple sclerosis.

InnoCare Pharma, a leading biopharmaceutical company, announced the Investigational New Drug approval of its Bruton’s tyrosine kinase inhibitor orelabrutinib by China National Medical Products Administration to start phase II clinical trial in Neuromyelitis Optica Spectrum Disorder in China.

BD, a leading global medical technology company, announced the appointment of William “Bill” Brown to its board of directors, effective Feb. 28, 2022.

SAB Biotherapeutics (SAB), today announced the publication of nonclinical data from a study conducted in collaboration with the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) Division of Viral Products highlighting that SAB-185 effectively neutralizes multiple SARS-CoV-2 strains and that it is superior to convalescent plasma in neutralizing COVID variants.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Compensation Committee of its Board of Directors granted an inducement award to Brent Warner, the Company’s new President, Gene Therapy.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, reported consolidated financial results for the year ended December 31, 2021.

NANO-X IMAGING LTD today announces that Company management will participate in two investor conferences in the month of March 2022.

Orange County, California based MediPines Corporation has announced the addition of Gary C. Sieck, PhD; George M. Zlupko, MD, FCCP; and Aidan Raney, MD, FACC to its medical and scientific advisory board.

Dragonfly Therapeutics, Inc. (“Dragonfly”) today announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program.

Tricida, Inc. announced that it will participate in a Kidney Disease / Fibrosis panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 11:10 am PT / 2:10 pm ET.